Journal
AAPS JOURNAL
Volume 18, Issue 6, Pages 1373-1378Publisher
SPRINGER
DOI: 10.1208/s12248-016-9961-7
Keywords
academic-industrial collaboration; ADME; biodistribution; CMC; oncology; PK/PD; preclinical; quality by design; targeted delivery; toxicology
Categories
Ask authors/readers for more resources
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements-only together can they realize the full potential of nanomedicines for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available